Factors Affecting the Population of Mesenchymal Stem Cells in Adipose-Derived Stromal Vascular Fraction

E. Çiğdem Karadağ Sarı1, Ercüment Ovalı2

1Department of Plastic, Reconstructive and Aesthetic Surgery,Acıbadem University Faculty of Medicine, Acıbadem Altunizade Hospital, İstanbul, Turkey
2Department of Hematology, Acıbadem University Faculty of Medicine, Acıbadem Labcell Cellular Therapy Facility, İstanbul, Turkey

INTRODUCTION

Plastic surgeons introduced the use of adipose tissue (AT) as a grafting tool.1 The stromal vascular fraction (SVF) consists of a multipotent stem and/or stromal cells.2 The SVF is isolated from AT and has tremendous regenerative potential for proliferation and differentiation due to the so-called adipose-derived stem cells (ADSCs).3 The mesenchymal stem cells (MSCs) are multipotent stem and/or stromal cells, and their ability to transform into mesodermic, endodermic, and exodermic cells gives them enormous potential in research and clinical applications in tissue repair.4 They have specific lineages for their paracrine activity and interact with the microenvironment when transplanted into injured areas.

MSCs can induce new progenitors, produce various new cells, and facilitate the disposition of certain exosomes. The particles contain growth factors, cytokines, chemokines, and micro-RNA, thereby significantly restoring injuries and physiological functions.5,6 Secretion of these molecules enhances angiogenesis, immunomodulation, cell proliferation, and differentiation in injured tissues. ADSCs lack class II major histocompatibility complex sites, enabling them to serve in the allogenic setting without immune compromise.7 However, emerging evidence suggests that the immunomodulatory effect of ADSCs is related to their regenerative ability.8 The MSCs ameliorate pain, protect the tissue from infections, and, most importantly, prevent cytokine storms.9,10 Moreover, MSCs can repair tissues, including connective tissue and cartilage, by generating new structures. MSCs stimulate tissue and cartilage formation and inhibit inflammation.10 This valuable attribute of MSCs has unlocked a new treatment era of arthrosis and...
related tissue injuries. Implantation is effective, considering the migration capability of transplanted cells into target areas.

MSCs can be isolated and harvested from various sources, such as the bone marrow, AT, peripheral blood, umbilical cord, synovial fluid, dental pulp, and endometrial tissues. However, not all sources provide clinically useful MSCs. The bone marrow yields the most enriched and characterized MSCs for clinical use. BMC was the most common procedure to prepare MSCs; however, bone marrow aspiration is highly invasive and results in low stem cell numbers.

Liposuction was extensively performed for patients worldwide, thereby increasing its popularity as an option for fat removal and body contouring. The main advantages of harvesting ADSCs rather than bone marrow are ease of access, safe and abundant harvesting, and low mortality risk. Unlike bone marrow, AT is easy to collate and use for tissue engineering in large quantities without requiring an ex vivo expansion step. reported a higher MSC (CD45-CD31-CD90+CD105+) population in AT-derived stromal vascular function (AT-SVF; 4.28%) than in bone marrow sources (0.42%), and the adipose-derived stem cell population (CD34+CD31-CD146-) was 32% in AT-SVF and 0.16% in bone marrow concentration (BMC). Recently, AT-SVF was studied as an alternate source of stem cells. AT-SVF contained approximately sixfold fewer nucleated cells than BMC; thus, adherent cells in AT-SVF were fourfold greater than BMC. Additionally, the colony-forming unit frequency of AT-SVF was higher than that of BMC at 0.5% and 0.01%, respectively.

MSCs are identified by their adherence to plastic and expression of cell surface markers, including CD29, CD44, CD90, CD49a-f, CD51, CD73 (SH3), CD105 (SH2), CD106, CD166, and Stro-1 and lack of expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR surface molecules based on the minimal criteria from the International Society of Cellular Therapy. MSCs have no immunogenic effect and could replace damaged tissue. These properties sparked the development of progressive methods to isolate and characterize MSCs from various sources for therapeutic applications in regenerative medicine.

No previous study has investigated the factors affecting the MSC population in AT-SVF. These markers were individually analyzed in other studies, but we have investigated MSC-specific markers to assess the MSC population in AT-SVF.

The number of MSCs in the SVF is critical for determining the treatment effectiveness. The design phase of this research aimed to identify the factors affecting the number of stem cells. We evaluated the MSC count (CD45-CD31-CD90+CD105+), total cell count, and factors affecting total cell viability. Analytical planning of the clinical use of the SVF also plays an essential role in planning effective patient treatment. Additionally, we reviewed the effectiveness of demographic factors and clinical and surgical data on the obtained cells and cell viability in the SVF.

**MATERIALS AND METHODS**

This study retrospectively reviewed the chart of 30 patients who underwent liposuction to harvest adipose-derived SVF at our stem cell center from September 2018 to August 2019. We analyzed electronic medical records for demographic, clinical, operative characteristics, and outcomes. Patient demographic and clinical data (age; gender; body mass index [BMI]; blood type; medical comorbidities, such as diabetes, hypertension, and coronary artery disease [CAD]; smoking; and alcohol use) were noted from the hospital database. We recorded the amount of lipoaspirate and the donor areas from where the SVF was harvested, including the entire abdomen and lower abdomen, for operative variables. The viability and cell count of SVF were documented.

**Fat Harvesting**

All operations were performed under sedoanalgesia in a sterile operating room. We used the tumescent technique and harvested lipoaspirates from the abdominal region. The same plastic surgeon performed all operations.

Umbilical and suprapubic areas were selected as entry sites. The tumescent solution, containing ringer lactate with 1:500,000 units of epinephrine and 20 mg of bupivacaine hydrochloride, was infiltrated through the 3-mm incisions and allowed to rest for 10 min to achieve hemostasis. The volume of tumescent solution injected was 150 cc.

Following the hemostasis, a blunt cannula (the “Fat Grater”) with a 2-mm diameter, of which the tip has 10 holes measuring 1.5 mm in diameter, was utilized to harvest the adipose aspirate. The attached cannula to a 60-ml syringe and the gentle pulling back on the syringe’s plunger provided a light negative pressure while the cannula was advanced and retracted through the harvest site. The cannula was removed from the syringe after filling the syringe with harvested tissue, and the lipoaspirate was transferred into sterile 50-ml Falcon tubes for further enzymatic processing.

**Isolation of the SVF**

All production processes were conducted following Good Manufacturing Practices. Fat tissue samples taken from the patient were placed in Falcon 50-ml Polypolyethylene Conical Tube (Avenida Industrial del Norte S/N, Parque Industry del Norte, Reynosa, Tamaulipas, Mexico). A sample was drawn from the tissue with an injector, and an input sample was given for microbiological quality control.

The AT samples in the tubes were arranged in Falcon tubes, and collagenase enzyme (SIGMA-ALDRICH, St. Louis, MO, USA) was placed in each Falcon tube. The collagenase enzyme had been sterility controlled, and the endotoxin level was approved as <10 IU/ml before use. The caps of the tubes were tightly closed, and the tubes were placed in the shaker. The shaker was adjusted to 100 rpm, and the tubes were incubated for 60-90 min.

After completing the incubation, the tubes were directly placed in the centrifuge device and centrifuged at 500 kg for 10 min. After centrifugation, the supernatant was removed using a pipette, and the pellet containing the cells was manually vortexed.

The pellet was removed and collected in a single tube via pipette. Filtering was done into a new tube with Cell Strainer, and the
volume was completed with Ringer Lactate Solution. The mix was spun again in a centrifuge for 10 min at 500xg.

Following the second round of spinning, the supernatant was removed, Ringer Lactate Solution was added to the pellet in the desired amount, and the mixture was centrifuged for a third time at 500xg for 10 min.

Quality Control Tests

The sample was drawn from the supernatant with an injector and run through the BD BACTEC Automated Blood Culture System (BD, East Rutherford, NJ, USA) for aerobic and anaerobic cultures and the fungus culture sample was obtained to assure microbiological quality control after the final centrifugation. Additionally, we analyzed endotoxin levels. The product was released for microbiological culture results once the Gram staining was negative in the sampling. The culture results were monitored for 2 weeks.

SVF Counting, Viability Assessment, and Immunophenotyping

Red blood cells were lysed via lysis buffer (eBioscience, CAT No: 000-433357). We used a hemocytometer to perform the cell count. We assessed cell viability using flow cytometry analysis for 7-aminoactinomycin D staining.

Immunophenotyping was performed on SVF for flow cytometry analysis. Cell surface antigen expression of AT-derived MSCs was detected using flow cytometry. We evaluated positive versus negative expression by flow cytometry using CD45, CD34, CD105, and CD90 monoclonal antibodies, with Cell Quest software (BD, East Rutherford, NJ, USA). Then, we calculated which cells were negative for CD45 and CD34 and which were positive for CD90 and CD105 as MSCs, and the percentage in the total population was calculated.

Statistical Analysis

Patient data collected within the scope of the study were analyzed with IBM Statistical Package for the Social Sciences for Windows, Version 23.0. (IBM Corp., Armonk, NY). Moreover, the power analysis was performed using Power Analysis and Sample Size Software version 11.0. (PASS, NCSS Statistical Software, Kaysville, UT; Table 1). The power analysis revealed an 81.6% power of the study. Frequency and percentage were given for categorical and continuous data and median, minimum, and maximum descriptive values for continuous data. The Shapiro-Wilk test examined the conformity of continuous quantitative variables to Gaussian distribution. The Mann-Whitney U test was used to compare two groups and the Kruskal-Wallis H test for three groups. The relationship between continuous variables was evaluated using Spearman’s Correlation test. The results were considered statistically significant with p-values of <0.05.

RESULTS

This retrospective analysis included 30 patients. The median age was 57 years (range, 25-85 years). Most of the study population was female (76.7%, n=23), and 23.3% (n=7) were male. The median BMI of the study population was 30 kg/m² (range, 18.6-51.9 kg/m²). Blood type A+ was the most common (56.7%, n=17), followed by O+ (26.7%, n=8), B+ (10%, n=3), AB+ (3.3%, n=1), and O- (3.3%, n=1). Hypertension is the most common comorbidity (40%, n=12), followed by CAD (30%, n=9), smoking (20%, n=6), diabetes (16.7%, n=5), and alcohol consumption (3.3%, n=1; Table 2).

Table 3 presents the correlation analysis to determine the nature of the relationship between MSC count (CD45 and CD34-/CD90 and CD105+), cell count, cell viability, and demographic and clinical findings. No statistically significant relationship was found between MSC count and other parameters (p>0.05; Table 3).

The median cell count was 45x10⁶, and the cell viability was 94% (range, 86-100). The lipoaspirate amount was 140 (range, 50-212). MSCs had a mean incidence of 2.25% (range, 0.25%-12.45%) in AT-SVF (Table 2).

We determined a positive linear correlation between cell count and age, and lipoaspirate amount (p<0.05) but found no statistically significant relationship with other variables (p>0.05). We noted a positive linear relationship between cell viability and BMI (p<0.05) but no other variable (Table 3).

The Mann-Whitney U and Kruskal-Wallis H tests were performed to evaluate the significant difference in demographic, clinical, and operative findings in cell count, cell viability, and MSC numbers are shown in Table 4. Hypertension was significantly associated with cell viability, and CAD was significantly associated with MSC count (p<0.05). Cell viability in patients with hypertension was higher than in those without hypertension, and the MSC count of individuals with CAD was higher than in those without CAD. No statistically significant difference was found in the number of cells, cell viability, and MSC (CD45 and CD34-/CD90 and CD105+) count among other variables (p>0.05).

### Table 1. Normality Test Results for Variables

| Variables (n=30) | Statistics | Degrees of freedom | p-value |
|-----------------|------------|--------------------|---------|
| Lipoaspirate amount | 0.180 | 30 | 0.020 |
| Cell count | 0.178 | 30 | 0.015 |
| CD45 vs. CD34 (−)/CD90 vs. CD105 (+) | 0.227 | 30 | <0.001 |
| MSC (viability) | 0.218 | 30 | 0.001 |

MSC: Mesenchymal stem cell
DISCUSSION

This study represents the first study conducted on the correlation of demographic, clinical, and surgical data on the obtained MSCs and cell viability in the AT-SVF. We found a positive correlation between MSC count and CAD, which was not previously reported in the literature. Previous studies have focused on MSC-based therapy for cardiovascular diseases rather than cell count. In another milestone discovery, this study found a positive correlation between cell viability and hypertension. However, the positive correlation could be due to increased intraluminal pressure, which might have facilitated cell viability. Additionally, calcium-channel blockers might deteriorate cellular attachment, thereby increasing harvested cells. Previous articles on MSCs and hypertension elaborated on the ameliorating effects of MSCs on hypertension-related pathologies and improvement in renovascular hypertension. Age is a strong determinant of ADSC quality because younger patients hold greater proliferative capacity and are more efficient at differentiating into mature adipocytes than older patients.
Therefore, younger patients are more suitable for tissue engineering applications than older patients. However, our results show a positive linear correlation between cell count and age which we did not expect and seems to contradict conventional knowledge. This relationship needs further exploration with larger populations and additional research to reconcile this trend against the current literature.

Andjelkov et al.\textsuperscript{22} assessed the correlation of age, gender, BMI, and smoking status with the SVF cell yield and viability, and they indicated that age significantly influenced SVF cell yield positively, as we found in our study. BMI and gender did not influence the cell yield or the SVF viability. Smoking was significantly negatively associated with SVF cell yield. Contrary to our results, smoking did not influence cell viability or yield in SVF. Our study revealed no significance between the MSC count and smoking or alcohol consumption. To our knowledge, no previous study has assessed such relationships. Further studies with larger sample sizes revealed that smoking and alcohol consumption affected the MSC count in AT-SVF. Additionally, we found that blood type did not influence MSC count, cell viability, or cell yield in SVF—an association that had not been explored previously in the literature.

Moreover, our study revealed higher cell count in patients with higher lipoaspirate amounts \((p<0.05)\). ADSCs’ proliferation capacity and functionality are heavily influenced by the patient’s BMI, with increased activity in some massively obese patients than in lean controls.\textsuperscript{23} Our study revealed a positive linear relationship between cell viability and BMI \((p<0.05)\), which might be due to the high BMI of the individuals. The median BMI of our study population was 30 kg/m\(^2\).

This study evaluated the specific surface markers of MSC in AT-SVF. A previous research individually investigated cell surface markers\textsuperscript{20,21,23,24} and checked only for CD90 expression which has

| Characteristics (n=30) | Median cell count, \(x\) 106/µl (range) | \(p\) -value | Cell viability median (range) | \(p\) -value | Mesenchymal stem cell count median (range) | \(p\) -value |
|------------------------|------------------------------------------|------------|-------------------------------|------------|------------------------------------------|------------|
| Gender                 |                                          |            |                               |            |                                          |            |
| Female                 | 44 (20-84)                               | 0.961      | 94 (86-100)                   | 0.692      | 2.15 (0.25-12.45)                       | 0.135      |
| Male                   | 49 (14-76)                               |            | 97 (90-98)                    |            | 3.55 (0.45-6.80)                       |            |
| Blood type             |                                          |            |                               |            |                                          |            |
| O+                     | 59 (40-73)                               | 0.173      | 97 (90-98)                    | 0.406      | 1.88 (0.25-6.30)                       | 0.508      |
| O-                     | 44 (44-44)                               |            | 98 (98-98)                    |            | 2.15 (2.15-2.15)                       |            |
| A+                     | 41 (14-76)                               |            | 92 (86-100)                   |            | 2.50 (0.55-12.45)                      |            |
| B+                     | 41 (27-84)                               |            | 91 (90-97)                    |            | 2.25 (1.55-6.80)                       |            |
| AB+                    | 35 (35-35)                               |            | 93 (93-97)                    |            | 1.75 (1.75-1.75)                       |            |
| Diabetes               |                                          |            |                               |            |                                          |            |
| No                     | 44 (14-84)                               | 0.781      | 94 (86-100)                   | 0.933      | 2.20 (0.25-12.45)                       | 0.182      |
| Yes                    | 48 (40-54)                               |            | 97 (89-97)                    |            | 2.50 (1.80-7.25)                       |            |
| Hypertension           |                                          |            |                               |            |                                          |            |
| No                     | 40.5 (14-84)                             | 0.107      | 92.5 (86-98)                  | 0.047      | 2.17 (0.25-7.25)                       | 0.512      |
| Yes                    | 51.5 (27-76)                             |            | 97 (90-100)                   |            | 2.30 (0.45-12.45)                      |            |
| Coronary artery disease|                                          |            |                               |            |                                          |            |
| No                     | 46 (14-84)                               | 0.683      | 94 (86-99)                    | 0.398      | 2.00 (0.25-7.25)                       | 0.028      |
| Yes                    | 41 (27-76)                               |            | 97 (90-100)                   |            | 3.20 (1.75-12.45)                      | 0.795      |
| Smoking                |                                          |            |                               |            |                                          |            |
| No                     | 45 (14-76)                               | 0.876      | 94.5 (89-100)                 | 0.173      | 2.30 (0.25-12.45)                       | 0.817      |
| Yes                    | 45 (20-84)                               |            | 91.5 (86-97)                  |            | 2.23 (1.45-7.25)                       |            |
| Alcohol consumption    |                                          |            |                               |            |                                          |            |
| No                     | 46 (14-84)                               | 0.133      | 94 (89-100)                   | 0.091      | 2.25 (0.25-12.45)                       |            |
| Yes                    | 20 (20-20)                               |            | 86 (86-86)                    |            | 2.35 (2.35-2.35)                       |            |
| Donor zone             |                                          |            |                               |            |                                          |            |
| Lower abdomen          | 42.5 (20-84)                             | 0.916      | 96 (89-100)                   | 0.275      | 2.08 (1.20-12.45)                      | 0.409      |
| Entire abdomen         | 49 (14-76)                               |            | 93 (86-98)                    |            | 2.58 (0.25-7.25)                       |            |
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of our institution (2021-20/31; 10/2021).

Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions: Concept- EÇ.K.S., E.O.; Design- EÇ.K.S.; Data Collection or Processing- EÇ.K.S.; Analysis or Interpretation- EÇ.K.S.; Literature Search- EÇ.K.S.; Writing- EÇ.K.S.; Critical Review- E.O.

Conflict of Interest: No conflict of interest was declared by the authors.

Funding: The authors declared that this study received no financial support.

REFERENCES

1. Chen YW, Wang JR, Liao X, et al. Effect of suction pressures on cell yield and functionality of the adipose-derived stromal vascular fraction. J Plast Reconstr Aesthet Surg. 2017;70:257-266. [CrossRef]
2. Dos-Anjos Vilaboa S, Navarro-Palou M, Llul R. Age influence on stromal vascular fraction cell yield obtained from human liposapirases. Cytotherapy. 2014;16;1092-1097. [CrossRef]
3. Alaaeddine N, El Atat O, Saliba N, et al. Effect of age and body mass index on the yield of stromal vascular fraction. J Cosmet Dermatol. 2018;70:1233-1239. [CrossRef]
4. Choi EW, Seo MK, Woo EY, Kim SH, Park EJ, Kim S. Exosomes from human adipose-derived stem cells promote proliferation and migration of skin fibroblasts. Exp Dermatol. 2018;27:1170-1172. [CrossRef]
5. Othmani AE, Rouam S, Abbad A, et al. Cryopreservation impacts cell functionality of long term expanded adipose-derived stem cells. J Stem Cell Res Ther. 2019;9:1-8. [CrossRef]
6. Wang L, Tu XH, Zhao P, Song JX, Zou ZD. Protective effect of transplanted bone marrow-derived mesenchymal stem cells on pancreatitis-associated lung injury in rats. Mol Med Rep. 2012;6:287-292. [CrossRef]
7. Mazini L, Rochette L, Admou B, Amai S, Malka G. Hopes and Limits of Adipose-Derived Stem Cells (ADSCs) and Mesenchymal Stem Cells (MSCs) in Wound Healing. Int J Mol Sci. 2020;21:1306. [CrossRef]
8. Gentile P, Sterodimas A. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease. Aging Dis. 2020;11:465-469. [CrossRef]
9. Gentile P, Sterodimas A. Adipose-derived stem cell markers (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020;20:711-716. [CrossRef]
10. Rogers CJ, Harman RJ, Bunnell BA, et al. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med. 2020;18:203. [CrossRef]
11. Copcu HE. Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19. Aging Dis. 2020;11:730-736. [CrossRef]
12. Masood M, Kang M, Wu X, Chen J, Teng L, Qui L. Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine. Life Sci. 2020;256:118002. [CrossRef]
13. Mazini L, Rochette L, Amine M, Malka G. Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019;20:2523. [CrossRef]
14. Taghavi-Farahabadi M, Mahmoudi M, Souadi S, Hashemi SM. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress
syndrome and lung injury using mesenchymal stem cell-derived exosomes. Med Hypotheses. 2020;144:109865. [CrossRef]

15. Jang Y, Koh YG, Choi YJ, et al. Characterization of adipose tissue-derived stromal vascular fraction for clinical application to cartilage regeneration. In Vitro Cell Dev Biol Anim. 2015;51:142-150. [CrossRef]

16. Delfune E, Prudenciatti A, Moroz A. Mesenchymal stem cell (MSC) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses. 2020;142:109769. [CrossRef]

17. Perry L, Buttrum SM, Nash GB. Effect of activation on adhesion of flowing neutrophils to cultured endothelium: time course and inhibition by a calcium channel blocker (nifedipine). Br J Pharmacol. 1993;110:1630-1634. [CrossRef]

18. Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008;60:538-544. [CrossRef]

19. Gardin C, Ferroni L, Chachques JC, Zavan B. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients? J Clin Med. 2020;9:2762. [CrossRef]

20. Pinky, Gupta S, Krishnakumar V, Sharma Y, Dinda AK, Mohanty S. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19. Stem Cell Rev Rep. 2021;17:33-43. [CrossRef]

21. Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9:1007-1022. [CrossRef]

22. Andjelkov K, Conde-Green A, Mosheibi A. Smoking and Physical Activity Significantly Influence Stromal Vascular Fraction Cell Yield and Viability. Aesthetic Plast Surg. 2021;45:315-321. [CrossRef]

23. Jayaramayya K, Mahalaxmi I, Subramaniam MD, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMJ Rep. 2020;53:408-412. [CrossRef]

24. Mildmay-White A, Khan W. Cell Surface Markers on Adipose-Derived Stem Cells: A Systematic Review. Curr Stem Cell Res Ther. 2017;12:484-492. [CrossRef]

25. van Harmelen V, Skurk T, Röhrig K, et al. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord. 2003;27:889-895. [CrossRef]

26. Debnath T, Chelluri LK. Standardization and quality assessment for clinical grade mesenchymal stem cells from human adipose tissue. Hematol Transfus Cell Ther. 2019;41:7-16. [CrossRef]